Terms: = Bone cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
36 results:
1. RAS‑stimulated release of exosomal
Kim O; Tran PT; Gal M; Lee SJ; Na SH; Hwangbo C; Lee JH
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37503759
[TBL] [Abstract] [Full Text] [Related]
2. hras overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Liverani C; Spadazzi C; Ibrahim T; Pieri F; Foca F; Calabrese C; De Vita A; Miserocchi G; Cocchi C; Vanni S; Ercolani G; Cavaliere D; Ranallo N; Chiadini E; Prisinzano G; Severi S; Sansovini M; Martinelli G; Bongiovanni A; Mercatali L
Front Endocrinol (Lausanne); 2022; 13():1045038. PubMed ID: 36743926
[TBL] [Abstract] [Full Text] [Related]
3. MSC-Derived exosomes suppress colorectal cancer cell proliferation and metastasis via miR-100/mTOR/miR-143 pathway.
Jahangiri B; Khalaj-Kondori M; Asadollahi E; Purrafee Dizaj L; Sadeghizadeh M
Int J Pharm; 2022 Nov; 627():122214. PubMed ID: 36152993
[TBL] [Abstract] [Full Text] [Related]
4. miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells.
Bazavar M; Fazli J; Valizadeh A; Ma B; Mohammadi E; Asemi Z; Alemi F; Maleki M; Xing S; Yousefi B
Pathol Res Pract; 2020 Nov; 216(11):153176. PubMed ID: 32861171
[TBL] [Abstract] [Full Text] [Related]
5. The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study.
Ronsley R; Kariminia A; Ng B; Mostafavi S; Reid G; Subrt P; Hijiya N; Schultz KR
Pediatr Hematol Oncol; 2019 Nov; 36(8):468-481. PubMed ID: 31530240
[No Abstract] [Full Text] [Related]
6. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice.
Gergely PA; Murnyák B; Bencze J; Kurucz A; Varjas T; Gombos K; Hortobágyi T
Biomed Res Int; 2019; 2019():8670398. PubMed ID: 30882001
[TBL] [Abstract] [Full Text] [Related]
7. The Mutational Profile of Unicystic Ameloblastoma.
Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
[TBL] [Abstract] [Full Text] [Related]
8. T cell leukemia control via Ras-Raf pathway inhibition with peptides.
Marin GH; Rebollo A; Bruzzoni-Giovanelli H; Schinella G; Piazzon I; Duarte A; Errecalde J
J Med Life; 2017; 10(3):172-175. PubMed ID: 29075346
[TBL] [Abstract] [Full Text] [Related]
9. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
[TBL] [Abstract] [Full Text] [Related]
10. Hobnail Variant of Papillary Thyroid Carcinoma: Clinicopathologic and Molecular Evidence of Progression to Undifferentiated Carcinoma in 2 Cases.
Cameselle-Teijeiro JM; Rodríguez-Pérez I; Celestino R; Eloy C; Piso-Neira M; Abdulkader-Nallib I; Soares P; Sobrinho-Simões M
Am J Surg Pathol; 2017 Jun; 41(6):854-860. PubMed ID: 28009606
[TBL] [Abstract] [Full Text] [Related]
11. [A Case of Early Anal Canal cancer with Pagetoid Spread with Different Antitumor Effects of Chemotherapy on Different Metastatic Sites].
Yoshimatsu K; Osawa G; Yokomizo H; Yano Y; Okayama S; Sakuma A; Satake M; Yamada Y; Asaka S; Usui T; Yamaguchi K; Shiozawa S; Shimakawa T; Katsube T; Naritaka Y
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1292-1294. PubMed ID: 27760964
[TBL] [Abstract] [Full Text] [Related]
12. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract] [Full Text] [Related]
13. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.
Lim YH; Ovejero D; Derrick KM; ; Collins MT; Choate KA
J Am Acad Dermatol; 2016 Aug; 75(2):420-7. PubMed ID: 27444071
[TBL] [Abstract] [Full Text] [Related]
14. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract] [Full Text] [Related]
15. A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.
Xu CW; Cai XY; Shao Y; Li Y; Shi MW; Zhang LY; Wang L; Zhang YP; Wang LP; Tian YW
Mol Med Rep; 2015 Sep; 12(3):4370-4375. PubMed ID: 26130140
[TBL] [Abstract] [Full Text] [Related]
16. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment.
Sainz B; Alcala S; Garcia E; Sanchez-Ripoll Y; Azevedo MM; Cioffi M; Tatari M; Miranda-Lorenzo I; Hidalgo M; Gomez-Lopez G; Cañamero M; Erkan M; Kleeff J; García-Silva S; Sancho P; Hermann PC; Heeschen C
Gut; 2015 Dec; 64(12):1921-35. PubMed ID: 25841238
[TBL] [Abstract] [Full Text] [Related]
17. Identification of Unique, Heterozygous Germline Mutation, STK11 (p.F354L), in a Child with an Encapsulated Follicular Variant of Papillary Thyroid Carcinoma within Six Months of Completing treatment for Neuroblastoma.
Buryk MA; Picarsic JL; Creary SE; Shaw PH; Simons JP; Deutsch M; Monaco SE; Nikiforov YE; Witchel SF
Pediatr Dev Pathol; 2015; 18(4):318-23. PubMed ID: 25751324
[TBL] [Abstract] [Full Text] [Related]
18. Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.
Gkotzamanidou M; Terpos E; Bamia C; Kyrtopoulos SA; Sfikakis PP; Dimopoulos MA; Souliotis VL
Leukemia; 2014 May; 28(5):1113-21. PubMed ID: 24089038
[TBL] [Abstract] [Full Text] [Related]
19. Mutations in k-ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells.
Kanzaki H; Ohtaki A; Merchant FK; Greene MI; Murali R
Exp Mol Pathol; 2013 Apr; 94(2):372-9. PubMed ID: 23219833
[TBL] [Abstract] [Full Text] [Related]
20. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract] [Full Text] [Related]
[Next]
